Laura P Andrews

This inventor holds 6 USPTO granted patents and 5 published patent applications and 3 EPO patents. Top assignees: Genzyme Corporation, Icahn School of Medicine at Mount Sinai. Active years: 2013-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Laura P Andrews. Retrieved from https://idiyas.com/inventor/laura-p-andrews

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 5)

% Patents Active = 100.0

EPO Patents = 3 (Patent Applications = 4)

Average Co-Inventor Count = 5.0

ph-index = 4

Forward Citations = 46(Granted Patents)

Company Filing History:

Icahn School of Medicine at Mount Sinai

patents

where one patent can have more than one assignee

Years Active: 2013-2019

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10188705 - Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency (2019-01-29),

2. 9655954 - Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency (2017-05-23),

3. 9114139 - Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency (2015-08-25),

4. 8709408 - Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency (2014-04-29),

5. 8658162 - Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency (2014-02-25),

6. 8349319 - Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency (2013-01-08),

Title: Laura P Andrews: Innovator in Enzyme Replacement Therapy

Introduction

Laura P Andrews is a prominent inventor based in Bolton, MA (US). She has made significant contributions to the field of enzyme replacement therapy, particularly in the treatment of acid sphingomyelinase deficiency. With a total of 6 patents to her name, her work has had a profound impact on medical science.

Latest Patents

One of her latest patents focuses on dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency. This invention relates to the use of acid sphingomyelinase (ASM) for the treatment of human subjects suffering from acid sphingomyelinase deficiency (ASMD). It specifically targets patients with non-neurological manifestations of Niemann-Pick Disease (NPD), including NPD type B.

Career Highlights

Throughout her career, Laura has worked with notable organizations such as Genzyme Corporation and the Icahn School of Medicine at Mount Sinai. Her expertise in enzyme replacement therapy has positioned her as a leader in her field.

Collaborations

Laura has collaborated with esteemed colleagues, including Edward Howard Schuchman and Robert J Desnick. These partnerships have further advanced her research and innovations in enzyme therapy.

Conclusion

Laura P Andrews is a trailblazer in the field of enzyme replacement therapy, with a focus on treating acid sphingomyelinase deficiency. Her contributions continue to influence medical practices and improve patient outcomes.

Profile summary based on public USPTO records.